President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its ...

The C-Suite Innovators' Playbook is brought to you in partnership with EVERSANA.

AI, integrated customer journeys, and breaking down internal silos aren’t just trends – they’re business imperatives. In this ...

In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, ...

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

The foundational model could also assist Google and partner Samsung in an ongoing rivalry with Apple, currently the leader in ...

When Tidmarsh was appointed to CDER, the FDA emphasised his academic and clinical credentials – including his role as ...

The problem of medical misinformation on the Internet was brewing before the COVID-19 pandemic, but the combustible discourse ...

AbbVie already has a working relationship with Gilgamesh, in the form of an R&D collaboration and opt-in licensing agreement ...

Many LSHC GCCs handle functions like clinical trials and operations, which mandate high regulatory scrutiny and explainability of the data generated. Sovereign AI makes this possible by allowing full ...